Stallergenes Greer Makes Senior Appointment
This article was originally published in Scrip
Stallergenes Greer Plc., a company specialising in allergy immunotherapy, has appointed Michele Antonelli executive vice president, head of international operations. Prior to Stallergenes Greer, Antonelli held various positions at UCB, with the most recent being executive vice president and head of immunology Europe. Before UCB, Antonelli spent 16 years at Merck Serono, ultimately in the role of senior vice president and global head of biotech manufacturing and process development in Geneva.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.